Revolutionary Insights from ASCO 2025 on Alrizomadlin
ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 - Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a pioneering biopharmaceutical company, recently showcased astounding clinical findings during the ASCO 2025 Annual Meeting. This event is a cornerstone of cancer research and clinical oncology, where the latest advancements are revealed to a prestigious audience. Ascentage Pharma presented crucial data from its Phase II study on alrizomadlin (APG-115), a novel MDM2-p53 inhibitor, highlighting its efficacy as both a monotherapy and in combination with the PD-1 inhibitor toripalimab, particularly in advanced adenoid cystic carcinoma (ACC) and other solid tumors.
The Significance of ASCO Annual Meeting
The ASCO Annual Meeting serves as a global platform for remarkable breakthroughs in oncology, attracting the brightest minds in cancer research. Ascentage Pharma has a notable history at ASCO, attending for the eighth consecutive year, and this year, it captured attention with two significant presentations on its innovative drug candidates, alrizomadlin and the Bcl-2 inhibitor lisaftoclax (APG-2575).
Clinical Data on Alrizomadlin
The clinical results presented shed light on the anti-tumor activity of alrizomadlin, where patients with advanced ACC or malignant peripheral nerve sheath tumor (MPNST) showed promising responses. Furthermore, the combination therapy of alrizomadlin with toripalimab was met with positive tolerance and significant therapeutic potential across various cancers such as biliary-tract cancer (BTC) and liposarcoma (LPS).
Expert Opinions on Alrizomadlin's Efficacy
Professor Ye Guo, MD, who led the investigation at Shanghai East Hospital, remarked on the pressing need for effective treatments in rare cancers like ACC. The objective response rate (ORR) of 16.7% and a remarkable disease control rate (DCR) of 100% demonstrate the potential of alrizomadlin in this patient population, proposing a revolutionary approach to treatment.
Additional Insights from Clinical Investigators
Professor Ning Li, MD, from the Chinese Academy of Medical Sciences Cancer Hospital, emphasized the benefits seen in sarcoma patients—particularly those with MPNST—where alrizomadlin displayed favorable activity as both a standalone treatment and in conjugation with PD-1 therapy. A significant highlight was the impressive longevity of treatment responses in certain individuals.
Message from Ascentage Pharma's CMO
Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, expressed enthusiasm regarding the recorded clinical data, underscoring alrizomadlin's potential as a first-in-class agent. Tackling unmet clinical requirements remains a priority, as ongoing clinical programs aim to expedite the introduction of innovative treatment options that hold promise for cancer patients worldwide.
Key Highlights from ASCO 2025 Presentation
The presentation centered around a pivotal Phase 2 study examining alrizomadlin (APG-115), revealing some striking statistics:
- Abstract #: 6102
- Presentation Type: Poster Presentation
- Session Focus: Head and Neck Cancer
- Principal Authors: Included professionals from esteemed institutions, showcasing a collaborative effort in this groundbreaking research.
- Highlights of Findings: Data up to early 2025 demonstrated that alrizomadlin was effective in a variety of tumors, exhibiting notable antitumor action and a well-tolerated safety profile.
The study involved 57 participants across several types of tumors, indicating that alrizomadlin not only exhibits effectiveness as a monotherapy but also shows synergies when partnered with other therapies.
About Ascentage Pharma
Ascentage Pharma, with its commitment to address pressing medical needs in oncology, continues to develop a promising portfolio that includes novel drugs targeting cancer apoptosis. The company's lead product, olverembatinib, has already made waves in the market as the first approved therapy for specific chronic myeloid leukemia conditions in China and is a testament to the company's innovative spirit.
With an expansive pipeline that includes next-generation kinase inhibitors, Ascentage Pharma remains focused on enhancing cancer treatment paradigms worldwide. Collaborative efforts with leading biopharmaceutical companies and research institutions further amplify its capabilities to deliver cutting-edge therapy outcomes.
Frequently Asked Questions
What is alrizomadlin?
Alrizomadlin (APG-115) is an investigational MDM2-p53 inhibitor designed to potentially treat various solid tumors, particularly advanced ACC and sarcomas.
What were the results of the ASCO 2025 study presented by Ascentage Pharma?
The study revealed an objective response rate (ORR) of 16.7% and a disease control rate (DCR) of 100% in patients treated with alrizomadlin for ACC.
How does alrizomadlin compare to existing treatments?
Alrizomadlin offers a new strategy aimed at cancers with limited effective treatments, showing encouraging response rates that surpass current options.
What future developments are expected for Ascentage Pharma?
Ascentage Pharma is committed to rapid progression in clinical programs to introduce novel treatments for cancer patients globally.
Is alrizomadlin approved for use?
No, alrizomadlin is still under investigation and has not yet received approval from the necessary regulatory authorities.
